BML Capital Management LLC reduced its stake in shares of LENZ Therapeutics, Inc. (NASDAQ:LENZ - Free Report) by 84.5% in the fourth quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission (SEC). The fund owned 9,271 shares of the company's stock after selling 50,729 shares during the quarter. LENZ Therapeutics comprises approximately 0.2% of BML Capital Management LLC's holdings, making the stock its 21st largest position. BML Capital Management LLC's holdings in LENZ Therapeutics were worth $268,000 at the end of the most recent reporting period.
Several other large investors have also recently added to or reduced their stakes in LENZ. Parkman Healthcare Partners LLC bought a new position in shares of LENZ Therapeutics during the third quarter worth about $3,308,000. Charles Schwab Investment Management Inc. grew its position in LENZ Therapeutics by 197.5% in the 3rd quarter. Charles Schwab Investment Management Inc. now owns 123,371 shares of the company's stock worth $2,929,000 after purchasing an additional 81,901 shares during the last quarter. State Street Corp grew its position in LENZ Therapeutics by 18.7% in the 3rd quarter. State Street Corp now owns 289,154 shares of the company's stock worth $6,865,000 after purchasing an additional 45,600 shares during the last quarter. Harbor Capital Advisors Inc. acquired a new stake in shares of LENZ Therapeutics in the fourth quarter valued at approximately $1,270,000. Finally, The Manufacturers Life Insurance Company bought a new stake in shares of LENZ Therapeutics during the third quarter valued at approximately $743,000. 54.32% of the stock is owned by institutional investors and hedge funds.
LENZ Therapeutics Stock Performance
Shares of NASDAQ LENZ traded up $0.39 during midday trading on Tuesday, hitting $22.97. 312,511 shares of the company's stock were exchanged, compared to its average volume of 160,517. LENZ Therapeutics, Inc. has a twelve month low of $14.42 and a twelve month high of $38.93. The stock's 50 day moving average price is $24.57 and its 200-day moving average price is $26.95.
LENZ Therapeutics Company Profile
(
Free Report)
LENZ Therapeutics, Inc, a biopharmaceutical company, focuses on developing and commercializing therapies to improve vision in the United States. Its product candidates include LNZ100 and LNZ101 which are in Phase III clinical trials for the treatment of presbyopia. The company is headquartered in Del Mar, California.
Read More
Before you consider LENZ Therapeutics, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and LENZ Therapeutics wasn't on the list.
While LENZ Therapeutics currently has a Buy rating among analysts, top-rated analysts believe these five stocks are better buys.
View The Five Stocks Here
MarketBeat just released its list of 10 cheap stocks that have been overlooked by the market and may be seriously undervalued. Enter your email address and below to see which companies made the list.
Get This Free Report
Like this article? Share it with a colleague.
Link copied to clipboard.
